Central Trust Company’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Central Trust Company’s Portfolio KRTX Stock Details KRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-75	Closed	-$23.7K	–	1430
2023 Q4	$23.7K	Hold	75	–	–	﹤0.01%	926
2023 Q3	$12.7K	Hold	75	–	–	﹤0.01%	1011
2023 Q2	$16.3K	Hold	75	–	–	﹤0.01%	960
2023 Q1	$13.6K	Hold	75	–	–	﹤0.01%	1001
2022 Q4	$14.7K	Hold	75	–	–	﹤0.01%	961
2022 Q3	$17K	Sell	75 -4	-5%	-$810	﹤0.01%	958
2022 Q2	$10K	Hold	79	–	–	﹤0.01%	1049
2022 Q1	$10K	Buy	79 +4	+5%	+$450	﹤0.01%	1083
2021 Q4	$10K	Hold	75	–	–	﹤0.01%	1064
2021 Q3	$9K	Hold	75	–	–	﹤0.01%	1060
2021 Q2	$9K	Buy	+75	New	+$8.77K	﹤0.01%	1039

Other funds holding KRTX

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

Central Trust Company's KRTX Position: Q1 2024 in Review

Central Trust Company sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q1 2024, closing a stake of 75 shares — an estimated $23.7K sold.

Central Trust Company first reported a position in KRTX in Q2 2021 and held it in 11 quarters. The position peaked at $23.7K in Q4 2023. 2 funds tracked by Wall St. Rank hold KRTX as of Q1 2024.

Central Trust Company reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Central Trust Company sold 75 Karuna Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $23.7K.
Central Trust Company first reported a position in Karuna Therapeutics, Inc. Common Stock in Q2 2021 and held it in 11 quarters.
Central Trust Company's Karuna Therapeutics, Inc. Common Stock position peaked at $23.7K in Q4 2023.
2 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Central Trust Company's 13F filing for Q1 2024, filed 24 Apr 2024.